(AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA ! Please readand realize the brutal potential !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
from Motley Fool "Even after the drop, BioCryst still has gained more than 13% in the past two days, and many see more upside for the small biotech going forward." Good news. Big upside coming!
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.6 In other words, the correlation coefficient of the other stock
From Motley Fool article: "Unfortunately, BioCryst will need to raise capital well before initiating a late-stage trial for BCX7353, given its last stated cash position of $98 million and burn rate that already exceeds $43 million per year. In other words, there's a good chance that the company is going to take advantage of this spike in its share price to raise capital, perhaps within the next few days. So, until then, investors interested in this small-cap biotech stock may want to bide their time for a more attractive entry point. "
Classic short squeeze. A thing of beauty !
will be $9 in no time. $# squeeze baby!
So, when will the dilution occur? Friday after hours is a favorite time for a dilution. So, my guess is at least one more day of pumping the price up. Now, will the dilution be at 6.0 or maybe 5.5?
This is/was short squeeze. The data released today aren't even statistically significant - less than 20 patients. No one's going to say, awesome results, let me buy the company.
why this is soaring any good news or just PUMP and DUMP?
Nice pump on no real news. Just a slight change to previous Phase 2 release. Perfect pump for a follow-on dilution.
Bitcoins are very hot now, Buy CNXS now, MIKE TYSON owns it , and you can too
I have a feeling BCRX will see a pullback now. What yall think? have you guys heard of aw-esomeSTOCKS. i started receiving their allerts and so far i am happy.
China Education Resources CHN V
BCRX is getting hammered lately, ouch!
See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states: • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days • Woundcare market is over $6 Billion with high growth rate • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost • Sales could commence late 2017 • Sales and or licensing agreement/s could be very significant and fast • Company is now commercializing several other disruptive products in large markets
Page 29 of the solicitation, Research Area 004, Section 2. Antiviral Broad-spectrum Therapeutics, states that a candidate antiviral therapeutic product must meet all of the criteria identified. Thus, an antiviral broad spectrum therapeutic that displays activity against Arenaviruses (part of the Category A viral pathogens under the NIAID Priority Pathogens List), must also display activity against infection caused by two or more viruses from the families identified in Section 2.b. to be considered responsive.